Prodded by attorneys from Sanofi-Aventis, Advancis has changed its name to MiddleBrook, which earns a few scoffs from the Health Blog of The Wall Street Journal. "Sounds more like a furniture store than a drug company," noted the writer. To Sanofi, though, Advancis sounded too much like Aventis and a judge agreed. MiddleBrook is now for sale, though, and the company notes that it's likely to take on the new name of anyone who acquires it. For the Advancis people, that would be their fifth, an final, name change.
- read the report from the Journal's blog (sub. req.)
FDA rejects Advancis' NDA on strep therapy. Report
FDA says Advancis ready to file. Report
Advancis readies Phase III Pulsys trial. Report
Advancis drug flunks trial. Report